Welcome to the NORD Physician Guide to Myelofibrosis. The NORD Online Physician Guides are written for physicians by physicians with expertise on specific rare disorders. This guide was written by John Mascarenhas, MD, of Mount Sinai School of Medicine (see acknowledgements for additional information).
NORD is a nonprofit organization representing all patients and families affected by rare diseases. The information NORD provides to medical professionals is intended to facilitate timely diagnosis and treatment for patients.
Myelofibrosis (MF) is categorized as a chronic myeloproliferative neoplasm (MPN). This is a group of heterogeneous, hematopoietic stem-cell malignancies.
MPNs are a group of heterogeneous, hematopoietic stem-cell malignancies that include chronic myelogenous leukemia (CML), essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF).
CML is characterized as a Philadelphia chromosome-positive MPN.
ET, PV and PMF comprise the Philadelphia chromosome-negative MPNs. ET and PV can evolve into MF, termed post-ET/PV MF. These cases, together with PMF, are collectively referred to as MF.
|There are reports on the following related topics in NORD’s online Rare Disease Database for patients, their families and the public at www.rarediseases.org:|